{
    "clinical_study": {
        "@rank": "26554", 
        "arm_group": {
            "arm_group_label": "Enzalutamide", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate radiographic progression-free survival (PFS) of\n      enzalutamide in chemotherapy-na\u00efve patients with progressive metastatic castration-resistant\n      prostate cancer who have symptomatic disease."
        }, 
        "brief_title": "A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Na\u00efve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Castration-Resistant Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Progressive prostate cancer while on androgen deprivation therapy\n\n          -  Castrate testosterone level\n\n          -  Maintenance of surgical or medical castration for duration of study\n\n          -  Radiographically visible metastatic disease\n\n          -  Symptomatic from prostate cancer\n\n          -  Eastern Cooperative Oncology Group (ECOG) 0-2\n\n          -  Life expectancy >=6 months\n\n        Exclusion Criteria:\n\n          -  Brain metastases or leptomeningeal disease\n\n          -  Prior cytotoxic chemotherapy for prostate cancer\n\n          -  Prior use of ketoconazole or abiraterone acetate or other investigational agent that\n             blocks androgen synthesis or targets androgen receptor\n\n          -  History of seizure or condition that may predispose to seizure\n\n          -  History of loss of consciousness or transient ischemic attack within 12 months\n\n          -  Clinically significant cardiovascular disease"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "0", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 9, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01663415", 
            "org_study_id": "9785-UC-0001"
        }, 
        "intervention": {
            "arm_group_label": "Enzalutamide", 
            "description": "oral", 
            "intervention_name": "Enzalutamide", 
            "intervention_type": "Drug", 
            "other_name": "MDV3100"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "MDV3100", 
            "prostate", 
            "cancer", 
            "enzalutamide"
        ], 
        "lastchanged_date": "September 14, 2012", 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2, Multicenter, Single-arm Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Na\u00efve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer", 
        "overall_official": {
            "affiliation": "Astellas Pharma Global Development", 
            "last_name": "Senior Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Withdrawn", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Time from first dose on Day 1 to the first objective evidence of radiographic progression or death due to any cause (whichever occurs first). Radiographic disease progression is defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and Prostate Cancer Clinical Trials Working Group 2 (PCWG2).", 
            "measure": "Radiographic progression free survival (PFS)", 
            "safety_issue": "No", 
            "time_frame": "26 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01663415"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Time from first dose on Day 1 to death due to any cause", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "26 months"
            }, 
            {
                "description": "Time from first dose on Day 1 to first observation of PSA progression", 
                "measure": "Time to PSA progression", 
                "safety_issue": "No", 
                "time_frame": "26 months"
            }, 
            {
                "description": "The FACT-P quality of life questionnaire is a multi-dimensional, self-reported quality of life instrument specifically designed for use with prostate cancer patients", 
                "measure": "Change from baseline to last post baseline measurement Quality of life score using Functional Assessment of Cancer Therapy-Prostate (FACT-P)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 26 months"
            }, 
            {
                "description": "EQ-5D is a standardized instrument for use as a measure of health outcome. It provides a simple descriptive profile and a single index value for health status and is designed for self-completion by respondents", 
                "measure": "Change from baseline to last post baseline measurement Quality of Life score using European Quality of Life 5-Domain Scale (EQ-5D)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 26 months"
            }, 
            {
                "description": "Brief Pain Inventory is a validated instrument that is a subject self-rating scale assessing level of pain, effect of the pain on activities of daily living, and analgesic use", 
                "measure": "Change from baseline to last post baseline measurement Pain Assessments (Brief Pain Inventory - Short Form)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 26 months"
            }, 
            {
                "measure": "Safety assessed by recording of adverse events, safety laboratory evaluations, vital signs and electrocardiograms (ECGs)", 
                "safety_issue": "No", 
                "time_frame": "26 months"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Medivation, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Global Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012", 
        "why_stopped": "A business decision was made to not initiate this study."
    }
}